You are currently viewing a new version of our website. To view the old version click .

High-Grade Serous Ovarian Cancer

This special issue belongs to the section “Cancer Therapy“.

Special Issue Information

Dear Colleagues,

Among ovarian cancers, high-grade serous ovarian cancer (HGSOC) is the most frequent histology with the poorest prognosis. In most cases, HGSOC is at an advanced stage 3–4 at the time of diagnosis, and the treatment policy requires not only surgery but also pharmacotherapy. Approximately 70% of HGSOCs respond to platinum combination pharmacotherapy, but once they have responded, many relapse and become drug-resistant and fatal. In recent years, omics analysis such as transcriptome analysis and whole-genome analysis of HGSOC has been performed, and research on the relationship with susceptibility to drug therapy has been progressing. This Special Issue calls for research on drug sensitivity or resistance, individualized treatment, and omics analysis of HGSOC.

Dr. Noriomi Matsumura
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • high-grade serous ovarian cancer
  • drug sensitivity
  • individualized treatment
  • omics analysis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694